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BACKGROUND: In this report we investigated the combination of epidermal growth factor receptor (EGFR) and mammalian target
of rapamycin (mTOR) pathway inhibition as a possible new therapeutic strategy for small cell lung cancer (SCLC).
METHODS:EGFR, p-AKT, p-ERK, p-mTOR and p-p70s6K protein expressions were studied by immunohistochemistry in 107 small cell
lung carcinomas and correlated with clinicopathological parameters. Cells of SCLC were treated with erlotinib±RAD001 and
analysed for cell viability, proliferation, autophagy, and pathway regulation.
RESULTS: Epidermal growth factor receptor, p-AKT, p-ERK, p-mTOR, and p-p70s6K were expressed in 37, 24, 13, 55 and 91% of the
tumour specimens of all SCLC patients, respectively, and were not associated with disease-free or overall survival. The expression of
EGFR was lower in neoadjuvant-treated patients (P¼0.038); mTOR pathway activation was higher in the early stages of disease
(P¼0.048). Coexpression of EGFR/p-mTOR/p-p70s6K was observed in 28% of all patients . EGFR immunoreactivity was associated
with p-ERK and p-mTOR expression (P¼0.02 and P¼0.0001); p-mTOR immunoreactivity was associated with p-p70s6K
expression (P¼0.001). Tumour cells comprised a functional EGFR, no activating mutations in exons 18–21, and resistance to
RAD001 monotherapy. We found synergistic effects of erlotinib and RAD001 combination therapy on the molecular level, cell
viability, proliferation and autophagy.
CONCLUSIONS: The combined inhibition of EGFR/mTOR pathways could be a promising approach to treat SCLC.
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The options for successful treatment of small cell lung cancer
(SCLC) are still very poor. From the time of diagnosis, the median
survival rates for SCLCs are 15–20 (limited disease SCLC) and
8–13 months (extended disease SCLC), respectively (Puglisi et al,
2010); therefore, new therapeutic strategies are urgently needed.
The epidermal growth factor receptor (EGFR) pathway is a well-
known molecular target in several human tumours. Small
molecules inhibiting EGFR such as erlotinib or gefitinib as well
as anti-EGFR antibodies such as cetuximab were successfully
tested in non-SCLC, head and neck, pancreatic and colon cancer
(Ciardiello and Tortora, 2008).
Until now, the EGFR pathway has not been studied extensively
in SCLC. There are little and controversial data about the presence
of EGFR in SCLC tissue (Fischer et al, 2007). It was shown that
treatment of SCLC cell lines with a monoclonal EGFR antibody
reduced invasiveness of tumour cells in vitro (Damstrup et al,
1998). The tyrosin kinase inhibitor gefitinib, directed against the
tyrosin kinase domain of the EGFR, showed single-agent activity
against SCLC cells (Tanno et al, 2004), and reverted resistance to
the chemotherapeutic topotecan in vitro (Nakamura et al, 2005),
but failed to show clinical benefit in a recent phase II clinical trial
in patients with SCLC (Moore et al, 2006). These data suggest that
targeting a single pathway in SCLC may not be efficient enough for
successful treatment of this deadly disease.
The mammalian target of rapamycin (mTOR) was intensively
studied in a multitude of human tumour entities over the past
couple of years. Different mitogens activate AKT, which controls
mTOR activation by phosphorylation of TSC2, a component of
tuberous sclerosis complexes 1 and 2. Activated mTOR phosphor-
ylates 4EBP-1 and p-p70s6K, which leads to protein translation
and tumour growth (Bjornsti and Houghton, 2004). AKT can also
be activated by the EGFR (Ono and Kuwano, 2006), which
represents a possible molecular link between the mTOR and the
EGFR pathways.
The mTOR inhibitors CCI-779 and everolimus (RAD001) have
already been approved for treatment of advanced renal cancer
(Hudes et al, 2007; Motzer et al, 2008); together with other mTOR
inhibitors, they are under clinical investigation for several other
cancer indications. Although there is evidence that the mTOR
pathway is active in SCLC cell lines (Fischer et al, 2007), mTOR
pathway expression in SCLC tissue has not been investigated until
now. The mTOR pathway may be involved in mechanisms of SCLC
cells to escape cell death after treatment with DNA-damaging
agents, as the mTOR inhibitor CCI-779 restored sensitivity of
SCLC cells to cisplatin treatment (Belyanskaya et al, 2005; Wu et al,
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s2005). However, similar to gefitinib therapy, CCI-779 and RAD001
monotherapy achieved only little benefit for SCLC in recent phase
II clinical trials (Pandya et al, 2005; Owonikoko et al, 2008).
Given the molecular connection of the EGFR and mTOR
pathways, we hypothesised that dual inhibition of both pathways
may be a suitable new strategy to treat SCLC. Thus, we investigated
single and coexpression of both pathways in 107 SCLC tissue
samples, their correlation with clinical–pathological parameters,
and analysed efficacy of anti-EGFR therapy plus mTOR inhibition
in SCLC cell lines.
MATERIALS AND METHODS
Patients and tissue samples
The study comprised 107 patients (69 males and 38 females),
median age 62 years (range 35–92 years), who underwent surgery
for SCLC at the Department of Cardio-Thoracic Surgery, Medical
University of Vienna, Austria. After surgery, tissue samples were
fixed in 7.5% buffered formalin and embedded in paraffin for
routine diagnostics. Neuroendocrine tumour differentiation was
confirmed by immunohistochemical staining for neuroendocrine
markers (chromogranin A and/or synaptophysin). Tumours were
staged according to the International Union Against Cancer (UICC)
2004 issue of the TNM system and revealed pT1 in 36 (34%), pT2 in
55 (51%), pT3 in 4 (4%) and pT4 in 12 (11%) cases; lymph node
metastases were present in 57 (53%) cases (pN1, pN2 and pN3 in 30,
21 and 2%, respectively). TNM stages corresponded to UICC stages
IA, IB, IIA, IIB, IIIA and IIIB in 22 (21%), 23 (21%), 9 (8%), 18
(17%), 22 (21%) and 13 (12%) cases, respectively. The clinical
follow-ups of the patients were retrospectively collected from the
archives of the Department of Cardio-Thoracic Surgery, Medical
University of Vienna, and respective hospitals performing their
follow-ups; median-disease free and overall survival were 11.5 and
20.5 months, respectively (both range 0–179.9 months). In all, 20
(19%) patients received preoperative chemotherapy (cisplatin and
etoposid). Adjuvant chemotherapy was known for 50 (47%) patients
(cisplatin and etoposid, cisplatin and adriamycin or cyclopho-
sphamid and oncovin; in some cases topotecan was given in second
line). In all, 56 (52%) patient suffered tumour recurrence and 48
(45%) died of tumour progression during the observation period.
Immunohistochemistry
Immunohistochemistry was performed on 4mm paraffin sections
from one representative tissue block per patient stored at the
archives of the Department of Pathology, Medical University of
Vienna, using antibodies against EGFR (DAKO, Glostrup,
Denmark) phospho-mTOR, phospho-p70s6K, phospho-AKT
and phospho-ERK (all from Cell Signaling Technology, Danvers,
MA, USA).
Epidermal growth factor receptor kit immunostaining was
performed according to the manufacturer’s instructions. Pretreat-
ment was protease (Sigma, Steinheim, Germany) for p-AKT
immunostaining, microwave (5 5min, 900W) for p-ERK
immunostaining, and autoclave (20min, 1 bar) for p-mTOR and
p-p70s6K immunostaining. After blocking, samples were incu-
bated with primary antibodies for 1h at room temperature.
Dilutions for anti-p-AKT, anti-p-ERK, anti-p-mTOR and anti-
p-p70s6K were 1:25, 1:100, 1:100 and 1:400, respectively. After
applying a biotinylated secondary antibody and tertiary reagent
(Vector-Laboratories, Bulingam, CA, USA) the antibody binding
was visualised by diaminobenzidine (Serva, Heidelberg, Germany)
and H2O2. Colon carcinoma tissue served as positive control.
Negative controls were treated with isotype IgG control antibodies.
Immunoreactive tumour cells were counted in 10 high-power fields
( 400) by KS and ZB independently. The scoring system
integrated intensity and extent of immunostaining: the number
of positive tumour cells was scored 0 (o10%), 1 (10–24%), 2
(25–49%), 3 (50–79%) and 4 (80–100%). Intensity of staining was
scored 0 (negative), 1 (weak) or 2 (strong). The results of the
extent and intensity of staining of tumour cells were summarised
to assess the final score.
Chemicals
RAD001 (everolimus) was provided by The Novartis Institutes for
BioMedical Research Basel, Oncology, Switzerland. Erlotinib was
dissolved in DMSO and provided by Professor Thomas Grunt
(Department of Medicine I, Institute of Cancer Research, Medical
University of Vienna, Austria). Controls were treated with
appropriate concentrations of DMSO.
Cell culture
Two SCLC cell lines were used: GLC-4, donated by Dr EG deVries,
Groningen, The Netherlands (Zijlstra et al, 1987), and VL-68
(Berger et al, 2001). Cells were grown in RPMI-1640 medium
supplemented with 10% heat-inactivated fetal calf serum and with
1% penicillin–streptomycin in a humidified atmosphere contain-
ing 5% CO2 (all from Gibco Life Technologies, Paisley, UK). Cell
counts were determined using a CC-108 microcellcounter (Sysmex,
Kobe, Japan). Cells growing in logarithmic phases of growth were
used for all the studies described below.
MTT assay
Cells (2 10
5 cells per well) in the logarithmic phase of growth
were plated in 0.5ml complete medium in 48-well plates and
allowed to attach overnight. The next day, RAD001, erlotinib or a
combination of both were added at concentrations as indicated.
The final concentration of DMSO never exceeded 0.5%. Cells were
incubated for 72h at 371C in a humidified atmosphere containing
5% CO2. Afterwards, medium was replaced by 100ml Opti-MEM
medium containing 1mgml
–1 Thiazolyl Blue Tetrazolium
Bromide (MTT; Sigma-Aldrich, Vienna, Austria) and incubated
for 1h at 371C. The cells were then lysed by adding 100ml DMSO.
Absorbance was recorded by a BioTek Synergy HT plate reader
(BioTek Instruments, Winooski, VT, USA) at 570nm. All
experiments were run in triplicates.
Cell cycle analysis, cell proliferation and apoptosis
Small cell lung cancer cells (0.4 10
6 per ml) were seeded in
25cm
2 tissue culture flasks and then incubated with RAD001,
erlotinib or with a combination of both at concentrations as
indicated. After 48h, cells were harvested and propidium iodide
staining was performed as reported by Sieghart et al (2007).
Cell cycle analysis (including sub-G1 peak for apoptosis)
was performed using a FACSCalibur flow cytometer (Becton
Dickinson, Heidelberg, Germany) and cell cycle distribution was
calculated using ModFit LT software (Verity Software House,
Topsham, ME, USA). To further analyse apoptosis, we performed
DAPI staining according to the study group of Dornetshuber et al
(2007). Cell proliferation was measured using the 3H-thymidine
incorporation assay (Dornetshuber et al, 2007) 24h after treatment
of SCLC cells with erlotinib, RAD001 or a combination of both at
indicated concentrations.
Quantification of autophagy by an analysis of acidic
vesicular organelle-positive cells
The effect of the investigated compounds alone and in combina-
tion on autophagy was assessed in both SCLC models by
quantification of acidic vesicular organelles. In brief, cells were
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sseeded at 3 10
5 per well in six-well plates and treated with
erlotinib, RAD001 and their combination at concentrations as
indicated. After 48h, cells were trypsinised, washed in PBS and
stained with acridine orange (1mgml
–1in serum- and phenol red-
free medium; Sigma-Aldrich) for 15min at 371C. The cells were
analysed through flow cytometry for green (510–530nm) and red
(4650nm) fluorescence emission from 2 10
4 cells illuminated
with blue (488nm) excitation light, and were measured with
FACSCalibur (Becton Dickinson) using CellQuest software. Cells
positive for red fluorescence were scored positive for acidic
vesicular organelles.
EGFR sequencing in SCLC cells
Genomic DNA used as template for sequencing EGFR exons 18–21
was extracted from the GLC-4 and VL-68 cell lines as described
previously (Lynch et al, 2004). In brief, polymerase chain reaction
(PCR) fragments were sequenced and analysed in both sense and
anti-sense directions for the presence of heterozygous mutations.
The primer sequences for exon 18 were 50-CTGAGGTGA
CCCTTGTCTCTG-30 (forward) and 50-CCAAACACTCAGTGAAA
CAAAGAG-30 (reverse); for exon 19 50-TGCCAGTTAACGTC
TTCCTT-30 (forward) and 50-CAGGGTCTAGAGCAGAGCAG-30
(reverse); for exon 20 50-CATTCATGCGTCTTCACCTG-30 (for-
ward) and 50-TTATCTCCCCTCCCCGTATC-30 (reverse); and for
exon 21 50-CTTCCCATGATGATCTGTCC-30 (forward) and 50-TTA
TCTCCCCTCCCCGTATC-30 (reverse). Mutations were identified
by visual analysis of the sequence chromatograms using SeqScape
(Applied Biosystems, Foster City, CA, USA).
Western blot
Cells (2 10
6 cells per well) in the logarithmic phase of growth
were plated in 2ml complete medium in six-well plates and
allowed to attach overnight. Cells were treated with RAD001,
erlotinib or with a combination of both at concentrations as
indicated. They were then incubated for 72h at 371Ci na
humidified atmosphere containing 5% CO2. After harvesting of the
probes they were blotted according to standard procedures and
incubated with monoclonal antibodies binding to EGFR (Santa
Cruz Biotechnology, Santa Cruz, CA, USA, 1:1000), p-AKT
(1:5000), p-mTOR (1:3000), p-p70s6K (1:3000), p-ERK (all from
Cell Signaling, 1:5000) or Actin (Sigma-Aldrich; 1:40000),
respectively. Reactive bands were detected by chemiluminescence
(CSPD substrate; Tropix Inc., Bedford, MA, USA). Equal protein
loading in each lane was documented by detecting Actin protein
expression.
Statistical analysis
Association of different protein immunoreactivity among each
other and with clinicopathological parameters was investigated
using the w
2 test. Disease-free and overall survival was assessed
using the Kaplan–Meier method. Cell culture data are presented as
mean±s.d. Differences among treatment groups were calculated
using one-way ANOVA, and Bonferroni’s test was used for post hoc
comparisons. For all tests, a two-tailed P-value of p0.05 was
considered significant.
RESULTS
EGFR pathway is expressed in SCLC
Overall, EGFR, p-AKT and p-ERK expression was detected in 37,
24 and 13% of tumour specimens (Figure 1 and Table 1). P-AKT
and p-ERK showed cytoplasmatic staining pattern, whereas EGFR
was expressed cytoplasmatic and membranous. The expression of
EGFR and p-ERK as well as of p-AKT and p-ERK was positively
associated (P¼0.02 and P¼0.0001), whereas EGFR and p-AKT
expression was not (P40.05, Table 2). Patients receiving
preoperative chemotherapy were less likely to present with
EGFR-positive tumours than patients without preoperative chemo-
therapy (14 vs 40%, P¼0.038), but no influence of preoperative
chemotherapy on p-AKT or p-ERK tumour expression was found
(both P40.05, Table 2). The expression of EGFR, p-AKT and
p-ERK was not associated with tumour stage, disease-free or
overall survival on univariate analysis (all P40.05, Table 2).
mTOR pathway is active in SCLC
Phospho-mTOR and p-p70s6K immunoreactivities were detected
in 55 and 91% tumour specimens of all SCLC patients (Figure 1
and Table 1). Phospho-mTOR was expressed in the cytoplasma
and p-p70s6K was detected in the cytoplasma and/or in the
nucleus. Mitoses showed a remarkable cytoplasmatic p-p70s6K
staining pattern (see arrows in Figure 1B). There was a significant
association of p-mTOR and p-p70s6K (P¼0.001, Table 2). Higher
tumour stages were associated with lower p-mTOR expression
(P¼0.048), but no association between p-mTOR expression and
nodal stage was found (P40.05, Table 2). Higher tumour and
nodal stages presented with lower p-p70s6K tumour expression
(P¼0.02 and P¼0.001, Table 2). Preoperative chemotherapy had
no influence on p-mTOR and p-p70s6K tumour expression.
Phospho-mTOR and p-p70s6K tumour expression had no
influence on disease-free and overall survival in univariate analysis
(P40.05, Table 2).
EGFR and mTOR pathways are coexpressed in SCLC
In all, 28% of all patients showed coexpression of both pathways in
terms of EGFR, p-mTOR and p-p70s6K positivity in SCLC tumour
specimens. There was no significant difference in tumour or nodal
stage distribution and administration of preoperative chemother-
apy compared with patients without pathway coexpression (all
P40.05). A positive association between EGFR and p-mTOR
expression (P¼0.0001), but not between EGFR and p-p70s6K
expression (P40.05, Table 2), was found. There was no association
between p-ERK, p-mTOR and p-p70s6K as well as p-AKT,
p-mTOR and p-p70s6K tumour expression (all P40.05, Table 2).
Synergistic effects of erlotinib and RAD001 combination
therapy on SCLC cells
Given a potential target population of 28% patients coexpressing
EGFR and mTOR pathways, we then evaluated the efficacy of
RAD001 and erlotinib in SCLC cell lines (Figure 2A and B).
Small cell lung cancer cells were treated with increasing doses
of RAD001 (5, 10, 20 and 50nM) and erlotinib (5 and 10mM)
for 72h.
RAD001 at doses of 5–50nM had no significant anti-tumour
effect. However, 5mM of erlotinib achieved a mild reduction of
viable GLC-4 (16%) and VL-68 cells (26%) (see Figure 2A and B,
Po0.001 compared with control) and this effect could not be
increased using 10mM of erlotinib. We did not use higher doses of
erlotinib, as 5mM erlotinib correspond to plasma concentrations in
humans that can be achieved after oral dosing with 150mg
erlotinib per day (Hidalgo et al, 2001).
Combination treatment of VL-68 and GLC-4 cells (Figure 2A
and B) revealed a strong, significant reduction of cell viability by
up to 86% (s.d.±0.74%) and 72% (s.d.±2%), respectively,
compared with the untreated control and the respective erlotinib
or RAD001 monotherapy (all Po0.0001).
For further mechanistic insights, we analysed respective drug
effects on cell DNA synthesis (
3H-thymidine incorporation assay),
cell cycle phases (PI staining), autophagy (acidic vesicular
organelles) and apoptosis (DAPI staining and sub-G1 peak in cell
EGFR/mTOR inhibition in SCLC
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scycle analysis). Treatment of VL-68 cells with 5mM erlotinib for
24h revealed a strong reduction of DNA synthesis by 74%
compared with control (Figure 2C). Addition of RAD001 at all
doses further decreased DNA synthesis of erlotinib to 14% of
untreated control (Po0.003, compared with erlotinib or RAD001
monotherapy, respectively), thus showing a cooperative inhibitory
effect of this drug combination on SCLC cell proliferation. Similar
results were observed for the GLC-4 cell line (data not shown) and
confirmed by cell cycle analysis. Cell cycle analysis showed a
significant G0/G1 arrest with a corresponding significant reduction
of S phase of tumour cells upon combination treatment compared
with respective controls (see Figure 2D). Although apoptosis was
no major contributor to the observed anti-tumour effects
(unremarkable DAPI staining, no evidence for a sub-G1 peak in
FACS analysis, data not shown), there was a significant effect of
combinatorial therapy on autophagy. Treatment of VL-68 and
GLC-4 cell lines with erlotinib and RAD001 led to a 22- and 47-fold
induction of autophagy compared with control whereas respective
monotherapies revealed only a little effect (Figure 2E).
Regulation of EGFR and mTOR pathways by erlotinib and
RAD001 monotherapy and upon combination
Given the strong synergistic antitumour effect of erlotinib and
RAD001 combination therapy compared with the respective
monotherapy, we evaluated the mechanism of action of this
combination by monitoring therapy-associated changes in both
pathways (Figure 3A–C); both cell lines showed a weak EGFR
expression on the protein level (Figure 3A). No mutations were
found in EGFR gene exon 18–21. We next tested whether the EGFR
was functional in both cell lines. Thus, SCLC cells were serum
starved for 24h, followed by specific EGFR stimulation using
100ngml
–1 EGF in the presence or absence of erlotinib
(Figure 3B). Stimulation of SCLC cells caused a significant
induction of p-ERK in both cell lines. Erlotinib blocked
EGF-derived p-ERK induction in the GLC-4 cell line and reduced
AB
CD
E
Figure 1 Immunostaining of EGFR and mTOR pathways in SCLC. Immunohistochemical staining of SCLC for (A) p-mTOR, (B) p-p70s6K (strongly
stained mitoses are marked by arrows), (C) p-AKT, (D) p-ERK and (E) EGFR (all magnification  400).
Table 1 EGFR and mTOR pathway immunostaining in 107 SCLC tissue
specimens
Immunohistochemical staining Negative Weak Strong
EGFR 67 (63%) 24 (22%) 16 (15%)
p-ERK 93 (87%) 8 (7%) 6 (6%)
p-AKT 81 (76%) 20 (19%) 6 (5%)
p-mTOR 48 (45%) 41 (38%) 18 (17%)
p-p70s6K 10 (9%) 40 (38%) 57 (53%)
Abbreviations: EGFR¼epidermal growth factor receptor; mTOR¼mammalian
target of rapamycin; p-AKT¼phosphorylated AKT; p-ERK¼phosphorylated
extracellular signal-regulated kinase; SCLC¼small cell lung cancer.
EGFR/mTOR inhibition in SCLC
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sp-ERK induction to baseline levels in the VL-68 cell line
(Figure 3B). The same was true for p-AKT in the GLC-4 cell line,
whereas p-AKT was not inducible in the VL-68 cell line, a cell line
lacking basal p-AKT expression. These data confirmed that the
EGFR was functional in both cell lines and activated downstream
targets upon activation with its ligand EGF.
Finally, we evaluated the effects of both drugs alone and upon
combination on both cell lines: erlotinib monotherapy of GLC-4
cells with 5mM resulted in a clear downregulation of p-AKT, and
significantly activated the mTOR pathway in terms of p-mTOR
upregulation (Figure 3C), whereas erlotinib monotherapy of the
p-AKT-negative VL-68 cell line with 5mM caused a significant
downregulation of p-ERK levels, and – similarly to the GCL-4 cell
line – significantly activated the mTOR pathway in terms of
p-mTOR upregulation (Figure 3C). RAD001 treatment of GLC-4
and VL-68 cells with 5nM resulted in the downregulation of
p-mTOR and p-p70s6K. In addition, RAD001 influenced the EGFR
pathway: there was a slight downregulation of p-ERK and p-AKT
in the VL-68 and GLC-4 cell line, respectively. The combination of
5mM erlotinib and 5nM RAD001 in GCl-4 cells caused a synergistic
downregulation of p-AKT compared with erlotinib and RAD001
monotherapy. In the VL-68 cell line, the combination therapy
synergised in terms of p-ERK downregulation compared with
erlotinib monotherapy. In both cell lines, the mTOR pathway
activation caused by erlotinib monotherapy was inhibited upon
combination with RAD001.
DISCUSSION
Preclinical studies suggested synergistic effects upon combined
EGFR and mTOR pathway inhibition in non-SCLC and breast
(Buck et al, 2006), squamous cell carcinoma (Jimeno et al, 2007),
glioblastoma (Wang et al, 2006), colon (Bianco et al, 2008),
pancreatic cancer (Azzariti et al, 2008) and biliary tract cancer
(Herberger et al, 2009). This is the first study testing the
combination of EGFR targeting therapy with mTOR inhibitors
for SCLC treatment.
First, we assessed single EGFR and mTOR pathway expression in
107 SCLC tissues. Surprisingly, EGFR receptor was expressed in
37% (see Table 2), which is more frequently than reported
previously (Kaseda et al, 1989). In contrast, we found lower p-AKT
and p-ERK expression when compared with other investigators
(Blackhall et al, 2003). Moreover, we showed that expression of
EGFR significantly correlated with its downstream target p-ERK.
These results confirm in vivo the signalling information reported
Table 2 Association between EGFR and mTOR pathways and clinical–pathological parameters (n¼107)
EGFR p-ERK p-AKT p-mTOR p-p70s6K ChemoTx pT-stage pN-stage DFS OS
EGFR P¼0.02 NS P¼0.0001 NS P¼0.038 NS NS NS NS
p-ERK P¼0.02 P¼0.0001 NS NS NS NS NS NS NS
p-AKT NS P¼0.0001 NS NS NS NS NS NS NS
p-mTOR P¼0.0001 NS NS P¼0.001 NS P¼0.048 NS NS NS
p-p70s6K NS NS NS P¼0.001 NS P¼0.02 P¼0.001 NS NS
Abbreviations: DFS¼disease-free survival; EGFR¼epidermal growth factor receptor; mTOR¼mammalian target of rapamycin; NS¼not significant; OS¼overall survival;
p-AKT¼phosphorylated AKT; p-ERK¼phosphorylated extracellular signal-regulated kinase.
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Figure 2 Effects on cell growth after treatment of SCLC cells with erlotinib, RAD001 and a combination of both. GLC-4 (A) and VL-68 (B) cells were
treated with increasing doses of RAD001, erlotinib or a combination of both for 72h and analysed for cell viability using the MTT assay. Data are given as
mean percentage of viable cells±s.d. *Statistical significance (Po0.05). (C) VL-68 cells were treated with erlotinib 5mM or increasing doses of RAD001 as
indicated or a combination of both for 24h, and thereafter were analysed using the
3H-thymidine assay. Data are given as mean counts per min±s.d.
*Statistical significance (Po0.05). (D) GLC-4 cells were treated with 5mM erlotinib, 10nM RAD001 or a combination of both for 24h and analysed by FACS
after propidium iodide staining. Data are given as mean percentage of cells±s.d. *Statistical significance (Po0.05). (E) VL-68 and GLC-4 cells were treated
with 5mM erlotinib and 100nM RAD001 or a combination of both for 48h and analysed for acidic vesicular organelles. Data are given as x-fold autophagy-
positive cells – one of three representative experiments is shown.
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sin various in vitro studies. Interestingly, patients receiving
neoadjuvant chemotherapy with cisplatin and etoposid showed
significantly lower EGFR expression than patients receiving no
chemotherapy. Whether this reflects a true loss of EGFR receptor
or a selection of EGFR-negative tumour cells remains to be
investigated. However, reduced EGFR expression after chemo-
therapy could be, at least in part, responsible for the recent failure
of a phase II clinical trial (Moore et al, 2006), testing gefitinib in
chemotherapy pretreated SCLC patients.
The mTOR pathway was active in a significant proportion of
patients in terms of p-mTOR (55%) and p-p70s6K (84%) expression
(see Table 2). Similar to the association of EGFR and p-ERK,
p-mTOR also showed its well-demonstrated association with
p-p70s6K in vivo. Interestingly, mTOR pathway activation was
stronger in earlier stages of disease. This finding could be important
for future trial designs testing mTOR inhibitors in SCLC: a recently
reported phase II clinical trial with the mTOR inhibitor everolimus
(Owonikoko et al, 2008) in SCLC patients – including predominantly
patients at an advanced stage of disease – failed to show significant
clinical activity. In summary, EGFR and mTOR pathways were active
in a significant proportion of patients with SCLC. Furthermore, 28%
of SCLC patients showed coexpression of both pathways and may
therefore represent the potential target population for combined
anti-EGFR and mTOR targeting therapy.
Thus, we evaluated the efficacy of single- and dual-pathway
inhibition in SCLC cell lines and investigated the mechanism of
action of this combination at the molecular level. We found a
synergistic antitumour effect upon combination of both drugs. The
underlying mechanisms of the observed effect are complex and
involve: (1) significant reduction of DNA synthesis (see Figure 2C),
(2) a G0/G1 arrest with consecutive reduction of S phase (see
Figure 2D), and (3) induction of autophagy (see Figure 2E),
a mechanism that has been recently reported for mTOR inhibitors
(Kim et al, 2006; Iwamaru et al, 2007; Crazzolara et al, 2009). In
combination, these effects significantly contributed to the
observed antitumour effect, whereas apoptosis did not seem to
play a major role (unremarkable DAPI staining, no evidence for a
sub-G1 peak in FACS analysis).
It is noteworthy that there was only a mild effect of erlotinib at a
physiological dose in both cell lines (see Figure 2A and B) despite
strong downregulation of p-AKT in GLC-4 cells and p-ERK in
VL-68 cells (see Figure 3C). This might be explained by the absence
of an activating EGFR mutation, which is a striking predictor for
sensitivity of tumour cells to EGFR targeting therapy (Lynch et al,
2004; Ono and Kuwano, 2006). Compatibly, the only reported case
showing clinical response was achieved in a patient carrying one of
these activating mutations (Okamoto et al, 2006). Furthermore, the
induction of mTOR signalling by erlotinib observed in this study
may have contributed to the blunting of antitumour activity.
Similar to erlotinib, the efficacy of RAD001 monotherapy was
not dose dependent and was lacking in both cell lines, despite
target regulation in terms of p-mTOR and p-p70s6K down-
regulation. In contrast to previous reports (Buck et al, 2006;
O’Reilly et al, 2006; Sieghart et al, 2007), there was no increase in
AKT phosphorylation, which could have caused RAD001
resistance, leaving the mechanism of resistance unclear. Taken
together, single EGFR or mTOR pathway inhibition seems
ineffective for SCLC treatment in vitro, which may explain recent
failures of mTOR and EGFR monotherapy in clinical trials of SCLC
(Moore et al, 2006; Owonikoko et al, 2008).
Crucially, dual inhibition of EGFR and mTOR pathways by erlotinib
and RAD001 combination therapy showed a synergistic and highly
s i g n i f i c a n ta n t i t u m o u re f f e c tt h a tc ould be explained on the molecular
level by synergistic regulation of both pathways (see Figure 3C).
In summary, we found that the EGFR and mTOR pathways are
active and coexpressed in a significant proportion of SCLC
patients. A combination of erlotinib and RAD001 showed a
synergistic antitumour effect, which was reflected on the molecular
level, whereas respective monotherapies failed to prove significant
antitumour efficacy. Therefore, this study provides a preclinical
rationale to test dual inhibition of EGFR and mTOR pathways in
SCLC in a prospective clinical trial.
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Figure 3 Effects on EGFR and mTOR pathways after treatment of SCLC
cells with erlotinib, RAD001 and a combination of both. (A) GLC-4 and
VL-68 cells do express EGFR. (B) GCL-4 and VL-68 cells were treated with
5mM erlotinib±EGF (100ngml
–1) for 10min and blotted for p-ERK,
p-AKT and respective total proteins. (C) VL-68 and GCL-4 cells were
treated with 5mM erlotinib, 5nM RAD001 or a combination of both for
24h, and then immunoblotted for total and phospho-protein expression of
AKT, ERK, mTOR and p70s6K.
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